Recommendations of the U.S. Public Health Service Task Force on the Use of Zidovudine to Reduce Perinatal Transmission of Human Immuno deficiency Virus

Vol. 43 / No. RR-11

MMWR

111

Executive Committee (Continued)

Mary A. Young, M.D.
Georgetown University Medical Center
Washington, DC

Carmen D. Zorrilla, M.D.
University of Puerto Rico
School of Medicine
San Juan, PR

U.S. Public Health Service Task Force on the Use of Zidovudine
To Reduce Perinatal Transmission of Human Immunodeficiency Virus

Lynne M. Mofenson, M.D. (chair)
National Institutes of Health
Bethesda, MD
James Balsley, M.D., Ph.D.
National Institutes of Health
Bethesda, MD
Patricia S. Fleming
Office of the Secretary
U.S. Department of Health and
Human Services
Washington, DC
Helene D. Gayle, M.D., M.RH.
Centers for Disease Control
and Prevention
Washington, DC
Steven Gitterman, M.D., Ph.D.
Food and Drug Administration
Rockville, MD

David Lanier, M.D.
Agency for Health Care Policy
and Research
Rockville, MD
Frances E. Page, B.S.N., M.P.H.
Office of National AIDS Policy
Washington, DC
Martha F. Rogers, M.D.
Centers for Disease Control
and Prevention
Atlanta, GA
Patricia Salomon, M.D.
Health Resources and Services
Administration
Rockville, MD